Is Polivy Approved for Children?
Polivy (polatuzumab vedotin-piiq), a monoclonal antibody-drug conjugate from Genentech/Roche, is FDA-approved only for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab. No pediatric approval exists, as safety and efficacy in patients under 18 have not been established.[1][2]
Are There Ongoing Pediatric Clinical Trials for Polivy?
No active or recruiting trials specifically test Polivy in children. ClinicalTrials.gov lists Polivy studies focused exclusively on adults (age 18+), targeting lymphomas like DLBCL. Past trials, such as GO29365 (NCT02257567), enrolled only adults.[3] Roche's development pipeline does not mention pediatric expansion for Polivy.[1]
Why No Pediatric Studies Yet?
Polivy's mechanism—targeting CD79b on B-cells to deliver chemotherapy—has not been evaluated in pediatric populations due to low incidence of target indications like DLBCL in children (rare under age 18). Regulatory labels explicitly state "safety and effectiveness have not been established in pediatric patients."[2] No pediatric investigational plans are listed under FDA or EMA pediatric requirements.
What Happens If a Child Needs Treatment Like Polivy?
Off-label use in children is possible but rare and unstudied, carrying unknown risks like higher toxicity from the vedotin payload. Pediatric oncologists turn to alternatives like CAR-T therapies (e.g., Yescarta, approved for ages 12+ in some lymphomas) or standard chemo regimens. Consult pediatric specialists or trials via NCI's Pediatric MATCH for B-cell malignancies.[4]
Related Drugs with Pediatric Access
| Drug | Pediatric Approval | Key Difference from Polivy |
|------|---------------------|----------------------------|
| Rituximab | Yes, ages 6+ for certain lymphomas | Monotherapy antibody; often combined with chemo, unlike Polivy's targeted delivery. |
| Yescarta (axicabtagene ciloleucel) | Yes, ages 12+ for relapsed B-ALL | CAR-T cell therapy; broader pediatric data but higher cost and risks. |
| Inotuzumab ozogamicin (Besponsa) | Limited trials, no full approval | Similar conjugate for ALL; pediatric studies ongoing but not for DLBCL. |
Patients or families can search ClinicalTrials.gov for "polatuzumab pediatric" (zero results as of latest data) or contact Roche's medical information line for updates.[3]
Sources:
[1] Genentech Polivy Product Information
[2] FDA Polivy Label (2023)
[3] ClinicalTrials.gov (Pediatric Filter)
[4] NCI Pediatric Trials